title: The influence of treatments in daily clinical practice on the Children's Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry.
abstract: BACKGROUND
  Juvenile psoriasis has a negative effect on the quality of life (QoL). The influence of treatments on QoL of these children has never been investigated before in a prospective observational study.
  
  
  OBJECTIVE
  To assess the Children's Dermatology Life Quality Index (CDLQI) in a cohort of patients with juvenile psoriasis and to evaluate the influence of treatments in daily clinical practice on CDLQI.
  
  
  METHODS
  We conducted a prospective observational study of children with psoriasis from a registry containing daily clinical practice data. Before and after treatment, QoL was assessed by the CDLQI and disease severity was documented by the Psoriasis Area and Severity Index (PASI). Three clusters of treatments were analysed: topical, dithranol and systemic therapy.
  
  
  RESULTS
  In total, 125 patients were enrolled in the registry. Cross-sectionally, a mean ± SD CDLQI score of 7·5 ± 5·0 and a mean ± SD PASI of 7·0 ± 5·8 were recorded. Itching and problems with treatment had the highest impact on the children's QoL. Longitudinally, 85 patients were analysed with a total of 137 treatment episodes. All treatments contributed to a significant decline in total CDLQI score, with the largest decrease seen in dithranol and systemic treatments. A significant correlation was found between ΔCDLQI and ΔPASI for all treatment modalities. The highest positive impact of treatments was found in a decline of itch and sleep disturbance.
  
  
  CONCLUSIONS
  In this first prospective observational study on CDLQI in juvenile psoriasis, a positive influence of treatments in daily clinical practice on QoL was demonstrated.
authors.affiliation: Department of Dermatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands. a.oostveen@derma.umcn.nl
authors.forename: A M
authors.initials: AM
authors.lastname: Oostveen
authors.forename: M E A
authors.initials: ME
authors.lastname: de Jager
authors.forename: P C M
authors.initials: PC
authors.lastname: van de Kerkhof
authors.forename: A R T
authors.initials: AR
authors.lastname: Donders
authors.forename: E M G J
authors.initials: EM
authors.lastname: de Jong
authors.forename: M M B
authors.initials: MM
authors.lastname: Seyger
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D017668:Age of Onset; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life; D012042:Registries; D012720:Severity of Illness Index
chemical_list: D003879:Dermatologic Agents